MCID: ECL001
MIFTS: 58

Eclampsia

Categories: Blood diseases, Cardiovascular diseases, Nephrological diseases, Rare diseases, Reproductive diseases, Respiratory diseases

Aliases & Classifications for Eclampsia

Summaries for Eclampsia

Disease Ontology : 12 A pre-eclampsia characterized by the presence of seizures.

MalaCards based summary : Eclampsia, also known as eclampsia in puerperium, is related to severe pre-eclampsia and hellp syndrome, and has symptoms including seizures An important gene associated with Eclampsia is STOX1 (Storkhead Box 1), and among its related pathways/superpathways are Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) and Warfarin Pathway, Pharmacodynamics. The drugs Methyldopa and Calcium Carbonate have been mentioned in the context of this disorder. Affiliated tissues include placenta, endothelial and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 77 Eclampsia is the onset of seizures (convulsions) in a woman with pre-eclampsia. Pre-eclampsia is a... more...

Related Diseases for Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 303, show less)
# Related Disease Score Top Affiliating Genes
1 severe pre-eclampsia 33.7 ALB HLA-G PGF SERPINC1
2 hellp syndrome 30.7 EDN1 ENG F2 FLT1 MTHFR PGF
3 placental insufficiency 30.5 F2 FLT1 PGF
4 pre-eclampsia 30.3 C19orf33 CORIN EDN1 ENG EPHX1 F2
5 microvascular complications of diabetes 5 29.8 ALB FLT1 PGF
6 retinal vein occlusion 29.7 F2 MTHFR SERPINC1
7 antiphospholipid syndrome 29.6 F2 MTHFR SERPINC1 THBD
8 thrombophilia 29.6 F2 MTHFR SERPINC1 THBD
9 disseminated intravascular coagulation 29.5 F2 SERPINC1 THBD
10 purpura 29.4 F2 SERPINC1 THBD
11 hepatorenal syndrome 29.4 ALB EDN1 F2
12 antithrombin iii deficiency 29.3 F2 MTHFR SERPINC1
13 central retinal vein occlusion 29.3 F2 MTHFR SERPINC1
14 portal vein thrombosis 29.3 F2 MTHFR SERPINC1
15 thrombosis 29.3 F2 MTHFR SERPINC1 THBD
16 placental abruption 29.3 ENG F2 FLT1 MTHFR PGF SERPINC1
17 budd-chiari syndrome 29.2 F2 MTHFR SERPINC1
18 placenta disease 29.2 MTHFR OXT PAPPA PGF SERPINC1
19 stroke, ischemic 29.1 F2 MTHFR SERPINC1 THBD
20 homocysteinemia 29.0 ALB F2 MTHFR SERPINC1
21 pulmonary embolism 29.0 ALB F2 MTHFR SERPINC1
22 hepatic infarction 28.9 F2 MTHFR OXT SERPINC1
23 thrombophilia due to activated protein c resistance 28.9 F2 MTHFR SERPINC1 THBD
24 heart disease 28.8 ALB EDN1 F2 MTHFR SERPINC1
25 arteries, anomalies of 28.7 ALB EDN1 FLT1 PGF SERPINC1
26 vascular disease 28.2 ALB EDN1 ENG F2 MTHFR SERPINC1
27 myocardial infarction 27.8 ALB EDN1 F2 MTHFR PAPPA PGF
28 preeclampsia/eclampsia 5 12.6
29 preeclampsia/eclampsia 4 12.6
30 mild pre-eclampsia 12.5
31 preeclampsia/eclampsia 1 12.2
32 preeclampsia/eclampsia 2 12.1
33 preeclampsia/eclampsia 3 12.1
34 gestational diabetes 11.5
35 chorea gravidarum 11.1
36 encephalopathy 10.5
37 glomeruloid hemangioma 10.4 ENG FLT1
38 twin-to-twin transfusion syndrome 10.4 ENG FLT1 PGF
39 hydatidiform mole, recurrent, 1 10.4
40 gestational trophoblastic neoplasm 10.4
41 hypoxia 10.3
42 diabetes mellitus 10.3
43 cortical blindness 10.3
44 mesenteric vascular occlusion 10.3 F2 MTHFR
45 yemenite deaf-blind hypopigmentation syndrome 10.3
46 sudden sensorineural hearing loss 10.2 F2 MTHFR
47 antipyrine metabolism 10.2 ALB F2
48 non-a-e hepatitis 10.2 ALB F2
49 epstein-barr virus hepatitis 10.2 ALB F2
50 retinal detachment 10.2
51 ischemic neuropathy 10.2 F2 MTHFR
52 abdominal tuberculosis 10.2 ALB F2
53 polymorphic reticulosis 10.1
54 retinal vascular disease 10.1 ALB FLT1 MTHFR PGF
55 diabetes mellitus, noninsulin-dependent 10.1
56 body mass index quantitative trait locus 1 10.1
57 periodontal disease 10.1
58 parametritis 10.1 F2 OXT
59 cryptogenic cirrhosis 10.1 F2 MTHFR
60 hypertension, essential 10.1
61 kidney disease 10.1
62 rere-related disorders 10.1
63 breast cancer 10.1
64 systemic lupus erythematosus 10.1
65 cerebral hemorrhage 10.1
66 pulmonary edema 10.1
67 epilepsy 10.1
68 hepatic tuberculosis 10.1 ALB F2
69 peripartum cardiomyopathy 10.0
70 chronic kidney failure 10.0
71 patau syndrome 10.0
72 hypertensive encephalopathy 10.0
73 thrombocytopenia 10.0
74 chorioamnionitis 10.0
75 cardiac arrest 10.0
76 placenta praevia 10.0
77 bell's palsy 10.0
78 acute pancreatitis 10.0
79 ischemia 10.0
80 choriocarcinoma 10.0
81 pancreatitis 10.0
82 lupus erythematosus 10.0
83 triploidy 10.0
84 headache 10.0
85 kwashiorkor 9.9 ALB F2
86 bilirubin metabolic disorder 9.9 ALB F2 OXT
87 leech infestation 9.9 F2 SERPINC1
88 intestinal impaction 9.9 F2 SERPINC1
89 malaria 9.9
90 cerebral palsy 9.9
91 hemolytic anemia 9.9
92 polycystic ovary syndrome 9.9
93 cysticercosis 9.9
94 thrombotic thrombocytopenic purpura 9.9
95 cholestasis 9.9
96 status epilepticus 9.9
97 endometriosis 9.9
98 infertility 9.9
99 periodontitis 9.9
100 diabetes insipidus 9.9
101 seizure disorder 9.9
102 pulmonary hypertension, primary, 1 9.9 EDN1 ENG THBD
103 alpha-2-plasmin inhibitor deficiency 9.9 F2 SERPINC1
104 intracranial embolism 9.9 F2 SERPINC1
105 giant hemangioma 9.9 F2 SERPINC1
106 prothrombin deficiency, congenital 9.9 F2 SERPINC1
107 burns 9.9 ALB SERPINC1
108 obstructive jaundice 9.9 ALB EDN1 F2
109 spinal cord infarction 9.9 F2 MTHFR SERPINC1
110 sagittal sinus thrombosis 9.9 F2 SERPINC1
111 livedoid vasculitis 9.9 F2 MTHFR SERPINC1
112 thrombophlebitis 9.9 F2 MTHFR SERPINC1
113 portal hypertension 9.9 ALB EDN1 F2
114 blood protein disease 9.9 F2 MTHFR SERPINC1
115 branch retinal artery occlusion 9.8 F2 MTHFR SERPINC1
116 retinal artery occlusion 9.8 F2 MTHFR SERPINC1
117 protein s deficiency 9.8 F2 MTHFR SERPINC1
118 intracranial hypertension 9.8 F2 MTHFR SERPINC1
119 alzheimer disease 9.8
120 down syndrome 9.8
121 autism 9.8
122 enterocolitis 9.8
123 familial mediterranean fever 9.8
124 myasthenia gravis 9.8
125 insulin-like growth factor i 9.8
126 sudden infant death syndrome 9.8
127 bornholm eye disease 9.8
128 helicobacter pylori infection 9.8
129 headache associated with sexual activity 9.8
130 anxiety 9.8
131 alpha-1-antitrypsin deficiency 9.8
132 pulmonary hypertension 9.8
133 arthritis 9.8
134 glomerulonephritis 9.8
135 liver disease 9.8
136 temporal lobe epilepsy 9.8
137 chlamydia pneumonia 9.8
138 intrahepatic cholestasis of pregnancy 9.8
139 chlamydia 9.8
140 hypertensive retinopathy 9.8
141 oligohydramnios 9.8
142 hemolytic-uremic syndrome 9.8
143 quadriplegia 9.8
144 uveitis 9.8
145 hypothyroidism 9.8
146 hyperuricemia 9.8
147 brain edema 9.8
148 human immunodeficiency virus infectious disease 9.8
149 cerebrovascular disease 9.8
150 premenstrual tension 9.8
151 perinatal necrotizing enterocolitis 9.8
152 fatty liver disease 9.8
153 hypoglycemia 9.8
154 gestational diabetes insipidus 9.8
155 myasthenia gravis congenital 9.8
156 reversible cerebral vasoconstriction syndrome 9.8
157 cytomegalovirus infection 9.8
158 postpartum psychosis 9.8
159 osteonecrosis 9.8 F2 MTHFR SERPINC1
160 hepatic coma 9.8 ALB F2
161 blue toe syndrome 9.8 F2 SERPINC1
162 varicose veins 9.8 F2 MTHFR SERPINC1
163 endocarditis 9.8 ALB F2 SERPINC1
164 patent foramen ovale 9.8 F2 MTHFR SERPINC1
165 fournier gangrene 9.8 ALB F2 SERPINC1
166 esophageal varix 9.8 ALB F2 SERPINC1
167 hypersplenism 9.8 ALB F2 SERPINC1
168 intermittent claudication 9.8 ALB F2 SERPINC1
169 retinal vascular occlusion 9.8 F2 MTHFR PGF SERPINC1
170 ischemic colitis 9.7 F2 SERPINC1
171 factor xi deficiency 9.7 F2 SERPINC1 THBD
172 autoimmune disease 9.7
173 exudative vitreoretinopathy 1 9.7
174 attention deficit-hyperactivity disorder 9.7
175 renal cell carcinoma, nonpapillary 9.7
176 laryngeal adductor paralysis 9.7
177 nail-patella syndrome 9.7
178 osteoporosis 9.7
179 pheochromocytoma 9.7
180 rheumatoid arthritis 9.7
181 schizophrenia 9.7
182 anencephaly 9.7
183 carnitine-acylcarnitine translocase deficiency 9.7
184 disorganization, mouse, homolog of 9.7
185 hemolytic uremic syndrome, atypical 1 9.7
186 hypogonadism, male 9.7
187 intracranial hypertension, idiopathic 9.7
188 myeloperoxidase deficiency 9.7
189 ocular motor apraxia 9.7
190 thrombocytopenia-absent radius syndrome 9.7
191 wiskott-aldrich syndrome 9.7
192 fabry disease 9.7
193 nance-horan syndrome 9.7
194 46,xy sex reversal 1 9.7
195 aging 9.7
196 asthma 9.7
197 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 9.7
198 coronary heart disease 1 9.7
199 aspirin resistance 9.7
200 preterm premature rupture of the membranes 9.7
201 diabetes mellitus, ketosis-prone 9.7
202 microvascular complications of diabetes 3 9.7
203 microvascular complications of diabetes 4 9.7
204 microvascular complications of diabetes 6 9.7
205 microvascular complications of diabetes 7 9.7
206 protein z deficiency 9.7
207 muscle hypertrophy 9.7
208 hemorrhage, intracerebral 9.7
209 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 9.7
210 infantile liver failure syndrome 1 9.7
211 alacrima, achalasia, and mental retardation syndrome 9.7
212 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.7
213 acute myocardial infarction 9.7
214 asphyxia neonatorum 9.7
215 coronary artery anomaly 9.7
216 gas gangrene 9.7
217 hepatitis 9.7
218 hepatitis b 9.7
219 hydrocephalus 9.7
220 insulinoma 9.7
221 ischemic heart disease 9.7
222 neuromyelitis optica 9.7
223 pol iii-related leukodystrophies 9.7
224 spinal muscular atrophy 9.7
225 thalassemia 9.7
226 familial partial lipodystrophy 9.7
227 sleep apnea 9.7
228 adrenal gland pheochromocytoma 9.7
229 autism spectrum disorder 9.7
230 nonalcoholic fatty liver disease 9.7
231 klippel-feil syndrome 9.7
232 glucose intolerance 9.7
233 rickets 9.7
234 chronic pyelonephritis 9.7
235 malignant hypertension 9.7
236 hemiplegia 9.7
237 ovarian disease 9.7
238 henoch-schoenlein purpura 9.7
239 arteriovenous malformation 9.7
240 subdural empyema 9.7
241 pyelonephritis 9.7
242 diphtheria 9.7
243 cardiac tamponade 9.7
244 myopia 9.7
245 nephrotic syndrome 9.7
246 pica disease 9.7
247 graves' disease 9.7
248 thyroid crisis 9.7
249 dementia 9.7
250 crescentic glomerulonephritis 9.7
251 splenic artery aneurysm 9.7
252 bacteriuria 9.7
253 46 xy gonadal dysgenesis 9.7
254 melanoma 9.7
255 hypogonadism 9.7
256 dental caries 9.7
257 melancholia 9.7
258 membranoproliferative glomerulonephritis 9.7
259 kidney cortex necrosis 9.7
260 anuria 9.7
261 iga glomerulonephritis 9.7
262 pleural empyema 9.7
263 cranial nerve palsy 9.7
264 shwartzman phenomenon 9.7
265 tricuspid valve insufficiency 9.7
266 rh isoimmunization 9.7
267 hyperglycemia 9.7
268 panic disorder 9.7
269 compartment syndrome 9.7
270 hypogonadotropism 9.7
271 muscular atrophy 9.7
272 influenza 9.7
273 vasculitis 9.7
274 rubella 9.7
275 amyloidosis 9.7
276 diastolic heart failure 9.7
277 sickle cell disease 9.7
278 aortic coarctation 9.7
279 congenital hydrocephalus 9.7
280 cytokine deficiency 9.7
281 diploid-triploid mosaicism 9.7
282 gestational trophoblastic tumor 9.7
283 heparin-induced thrombocytopenia 9.7
284 hereditary antithrombin deficiency 9.7
285 neuromyelitis optica spectrum disorder 9.7
286 precocious puberty 9.7
287 recurrent hydatidiform mole 9.7
288 febrile seizures 9.7
289 cocaine intoxication 9.7
290 mesial temporal lobe epilepsy with hippocampal sclerosis 9.7
291 pulmonary artery disease 9.7 ALB F2 MTHFR SERPINC1
292 vein disease 9.7 ALB F2 MTHFR SERPINC1
293 hemorrhagic disease 9.6 F2 SERPINC1 THBD
294 marantic endocarditis 9.6 F2 MTHFR SERPINC1 THBD
295 protein c deficiency 9.6 F2 MTHFR SERPINC1 THBD
296 blood coagulation disease 9.6 F2 MTHFR SERPINC1 THBD
297 thrombophilia due to thrombin defect 9.6 F2 MTHFR SERPINC1 THBD
298 ischemic optic neuropathy 9.5 EDN1 F2 MTHFR SERPINC1
299 nonarteritic anterior ischemic optic neuropathy 9.5 EDN1 F2 MTHFR SERPINC1
300 dysfibrinogenemia 9.5 ALB F2 SERPINC1 THBD
301 peripheral vascular disease 9.5 ALB F2 SERPINC1 THBD
302 liver cirrhosis 9.4 ALB EDN1 F2 SERPINC1
303 hepatic vascular disease 9.3 ALB EDN1 F2 MTHFR SERPINC1

Graphical network of the top 20 diseases related to Eclampsia:



Diseases related to Eclampsia

Symptoms & Phenotypes for Eclampsia

UMLS symptoms related to Eclampsia:


seizures

MGI Mouse Phenotypes related to Eclampsia:

47 (showing 6, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.11 CORIN EDN1 ENG F2 FLT1 NOSTRIN
2 homeostasis/metabolism MP:0005376 10.06 ALB CORIN EDN1 ENG EPHX1 F2
3 growth/size/body region MP:0005378 10.03 CORIN EDN1 ENG F2 FLT1 INHBB
4 digestive/alimentary MP:0005381 9.92 ALB EDN1 ENG F2 INHBB OXT
5 integument MP:0010771 9.56 CORIN ENG F2 INHBB MTHFR OXT
6 normal MP:0002873 9.23 ALB EDN1 ENG F2 FLT1 PAPPA

Drugs & Therapeutics for Eclampsia

Drugs for Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 423, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyldopa Approved Phase 4,Phase 2,Phase 1,Not Applicable 555-30-6 38853
2
Calcium Carbonate Approved, Investigational Phase 4,Not Applicable 471-34-1
3
Remifentanil Approved Phase 4,Phase 2 132875-61-7 60815
4
Metformin Approved Phase 4,Phase 3,Phase 2,Not Applicable 657-24-9 14219 4091
5
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-78-2 2244
6
Dalteparin Approved Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 9005-49-6
7
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 9005-49-6 46507594 772
8
Enoxaparin Approved Phase 4,Phase 3,Not Applicable 9005-49-6 772
9
leucovorin Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-05-9 143 6006
10
Pseudoephedrine Approved Phase 4,Phase 3,Not Applicable 90-82-4 7028
11
Phenylephrine Approved Phase 4,Not Applicable 59-42-7 6041
12
Ephedrine Approved Phase 4,Phase 3,Not Applicable 299-42-3 9294
13
Oxymetazoline Approved, Investigational Phase 4,Not Applicable 1491-59-4 4636
14
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 50-56-6 53477758 439302
15
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7487-88-9 24083
16
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
17
Ibuprofen Approved Phase 4,Phase 2,Phase 3 15687-27-1 3672
18
Acetaminophen Approved Phase 4,Phase 2,Phase 3 103-90-2 1983
19
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
20
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
21
Clonidine Approved Phase 4,Phase 1,Phase 2 4205-90-7 2803
22
Captopril Approved Phase 4 62571-86-2 44093
23
Nifedipine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 21829-25-4 4485
24
Labetalol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36894-69-6 3869
25
Procaterol Approved, Investigational Phase 4 72332-33-3 688561
26
Insulin Aspart Approved Phase 4,Phase 3 116094-23-6 16132418
27
Zinc Approved, Investigational Phase 4,Phase 3,Not Applicable 7440-66-6 32051
28
Insulin Lispro Approved Phase 4 133107-64-9
29
Azithromycin Approved Phase 4,Phase 3 83905-01-5 447043 55185
30
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
31
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
32
tannic acid Approved Phase 4,Phase 3,Not Applicable 1401-55-4
33
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
34
Desogestrel Approved Phase 4 54024-22-5 40973
35
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-70-2 271
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
37
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1406-16-2
38
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1,Phase 2,Not Applicable 50-14-6 5280793
39
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 1,Phase 2,Not Applicable 67-97-0 5280795 6221
40
Serine Approved, Nutraceutical Phase 4,Phase 3,Early Phase 1 56-45-1 5951
41 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
45 Sympatholytics Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
51 Bone Density Conservation Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
52 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
53 Anesthetics, Intravenous Phase 4,Phase 3,Not Applicable
54 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
55 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Not Applicable
56 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
57 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
58 Narcotics Phase 4,Phase 3,Phase 2,Not Applicable
59 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
60 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
61 Antipyretics Phase 4,Phase 3,Phase 2,Not Applicable
62 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
63 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
64 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
65 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
66 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
67 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
68 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
69 calcium channel blockers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
70 Antibodies Phase 4,Phase 2,Phase 3,Not Applicable
71 Nutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
72 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
73 Immunoglobulins Phase 4,Phase 2,Phase 3,Not Applicable
74 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
75 Folate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
76 Immunologic Factors Phase 4,Phase 2,Phase 3,Not Applicable
77 Antibodies, Antiphospholipid Phase 4
78 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
79 Hematinics Phase 4,Phase 3,Not Applicable
80 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
81 calcium heparin Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable
82 Anticoagulants Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
83 Heparin, Low-Molecular-Weight Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable
84 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
85 Anesthetics, Local Phase 4,Phase 3,Not Applicable
86 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
87 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
88 Sympathomimetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
89 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
90 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
91 Bronchodilator Agents Phase 4,Not Applicable
92 Anti-Asthmatic Agents Phase 4,Not Applicable
93 Respiratory System Agents Phase 4,Not Applicable
94 Insulin, Globin Zinc Phase 4,Phase 3,Phase 1,Not Applicable
95 insulin Phase 4,Phase 3,Phase 1,Not Applicable
96 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
97 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
98 Vasoconstrictor Agents Phase 4,Phase 3,Not Applicable,Early Phase 1
99 Cardiotonic Agents Phase 4,Phase 2,Phase 3,Not Applicable
100 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
101 Nasal Decongestants Phase 4,Not Applicable
102 Central Nervous System Stimulants Phase 4,Phase 3,Not Applicable
103 Mydriatics Phase 4,Not Applicable
104 Ergocalciferols Phase 4,Phase 1,Phase 2,Not Applicable
105 Vitamin D2 Phase 4,Phase 1,Phase 2,Not Applicable
106 Calciferol Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
107 Oxytocics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
108 Progestins Phase 4,Phase 2,Phase 3,Not Applicable
109 Neuromuscular Nondepolarizing Agents Phase 4
110 Neuromuscular Blocking Agents Phase 4
111 Neuromuscular Agents Phase 4,Phase 1
112 Tocolytic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
113 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
114 Natriuretic Agents Phase 4,Phase 3,Phase 2,Not Applicable
115 diuretics Phase 4,Phase 3,Phase 2,Not Applicable
116 Sodium Potassium Chloride Symporter Inhibitors Phase 4,Phase 2
117 Pharmaceutical Solutions Phase 4,Phase 3,Not Applicable,Early Phase 1
118 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2
119 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
120
protease inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
121 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
122 Adrenergic beta-2 Receptor Agonists Phase 4
123 Adrenergic beta-Agonists Phase 4
124 Albuterol Phase 4
125 Insulin, Short-Acting Phase 4,Phase 3
126 Protamines Phase 4
127 Isophane insulin, beef Phase 4
128 Isophane Insulin, Human Phase 4
129 Insulin, Isophane Phase 4
130 Follicle Stimulating Hormone Phase 4,Phase 3
131 Vaccines Phase 4,Phase 2,Not Applicable
132 Antithrombin III Phase 4,Phase 3
133 Antithrombins Phase 4,Phase 3
134 Serine Proteinase Inhibitors Phase 4,Phase 3,Early Phase 1
135 Contraceptives, Oral Phase 4,Phase 3,Not Applicable
136 Contraceptive Agents Phase 4,Phase 3,Not Applicable
137
Ethylene Phase 4 74-85-1 6325
138
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
139
Nicardipine Approved, Investigational Phase 3 55985-32-5 4474
140
Hydroxocobalamin Approved Phase 3,Phase 2,Not Applicable 13422-51-0 15589840 11953898
141
Methylcobalamin Approved, Experimental, Investigational Phase 3,Not Applicable 13422-55-4
142
Carbetocin Approved, Investigational Phase 3 37025-55-1 16681432 71715
143
Magnesium citrate Approved Phase 3 3344-18-1
144
Sodium Citrate Approved, Investigational Phase 3,Phase 2,Not Applicable 68-04-2
145
Progesterone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Not Applicable 57-83-0 5994
146
Dinoprostone Approved Phase 3,Phase 1,Phase 2 363-24-6 5280360
147
Misoprostol Approved Phase 3,Phase 1,Phase 2,Not Applicable 59122-46-2 5282381
148
Metaraminol Approved, Investigational Phase 3,Not Applicable 54-49-9 5906
149
Bupivacaine Approved, Investigational Phase 3,Not Applicable 38396-39-3, 2180-92-9 2474
150
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3,Not Applicable 437-38-7 3345
151
Ropivacaine Approved Phase 3 84057-95-4 175805 71273
152
Dexmedetomidine Approved, Vet_approved Phase 2, Phase 3 113775-47-6 5311068 68602
153
Atorvastatin Approved Phase 3 134523-00-5 60823